In a separate case in which CareDx and Natera are suing each other for false advertising, a court has set a trial date in late October.
The companies are creating a platform that will test for both anti-nucleocapsid and anti-spike antibodies in the same reaction.
The point-of-care system can detect SARS-CoV-2 in unprocessed patient saliva in about an hour, according to the researchers.
The company hopes to complete the trial in early 2022 and submit data to the FDA for approval of its assay, which could compete with Exact Sciences' Cologuard.
Synthetic biology and CRISPR have enabled researchers to develop wearable sensors that can detect a variety of viruses and bacteria, including SARS-CoV-2.
The company said it is developing a new genomic test to predict therapeutic response in patients with inflammatory skin conditions.
The company recently acquired PFS Genomics, which has developed a test to determine the necessity of radiotherapy for breast cancer patients.
As diagnostics firms develop a new wave of COVID-19 tests using next-gen sequencing, TGen researchers are also adding CRISPR-based sample prep to their kit.
The 20-year study showed the test provided an accurate assessment of the risk of long-term metastases and mortality for patients with localized prostate cancer.
The company is also continuing to expand its digital technology offering to help clinicians track their patients' health more easily.